Boehringer continues fibrosis drive via acquisition of Enleofen assets

The acquisition of Enleofen’s preclinical IL-11 inhibition platform is the latest in a string of deals by Boehringer to build out its fibrosis tool kit, giving the German pharma therapies against a new target for the indication.

Enleofen Bio Pte. Ltd. is eligible for more than $1 billion per product from Boehringer Ingelheim GmbH in

Read the full 545 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE